CooperSurgical, part of CooperCompanies (NASDAQ: COO), has received FDA clearance for the Wallace Aspiration Pump, a digitally controlled suction system designed for oocyte retrieval during assisted-reproduction procedures. The device incorporates a touchscreen interface, two preset pressure settings corresponding to two needle configurations and additional customization options including language and display brightness. CooperSurgical says it is preparing the system for commercialization as part of its broader fertility portfolio.
An aspiration pump can appear less consequential than embryo-selection AI, genetic testing or a new incubator, but oocyte retrieval is one of the procedural steps where mechanical conditions interact directly with a highly delicate biological specimen. During transvaginal ultrasound-guided retrieval, a physician places a needle into ovarian follicles and applies suction to recover follicular fluid containing the cumulus-oocyte complex. Too little negative pressure can reduce the probability of recovering the oocyte efficiently, while excessive suction or inappropriate flow dynamics can theoretically increase mechanical stress on the oocyte and surrounding cumulus cells.
Why does aspiration pressure matter during egg retrieval?
Oocytes are not simply loose particles waiting inside ovarian follicles. The oocyte is surrounded by cumulus cells and extracellular material, creating a cumulus-oocyte complex that has to separate from the follicular environment and travel through the aspiration needle and tubing into a collection vessel.
The suction pressure interacts with needle diameter, tubing dimensions, fluid viscosity and follicular anatomy to determine flow speed and mechanical forces. A pressure setting that works appropriately through one needle may therefore create different flow characteristics through another.
This helps explain CooperSurgical’s emphasis on two preset pressure options aligned with different needle types. The aim is not to automate clinical judgment completely but to reduce the number of manual variables involved in reproducing a chosen retrieval condition from patient to patient.
Reliable pressure control could also matter to laboratory workflow. Retrieval teams frequently coordinate multiple follicles in sequence, and variation in suction response can affect the speed and predictability with which follicular fluid reaches the embryology laboratory.
What does human evidence say about 120 versus 150 mmHg aspiration?
A 2025 retrospective study from Seoul National University Hospital examined 400 IVF or ICSI retrieval cycles performed at either 120 or 150 mmHg. Investigators analyzed 202 cycles at the lower pressure and 198 at the higher setting. The 150 mmHg group produced an average of 7.7 retrieved oocytes compared with 6.3 at 120 mmHg, while mature oocytes averaged 5.6 versus 4.4. Numbers of embryos and good-grade embryos were also statistically higher in the higher-pressure group.
Importantly, the study did not demonstrate statistically significant differences in clinical pregnancy or live birth after multivariable analysis. That prevents a straightforward conclusion that setting a pump to 150 mmHg produces better IVF success. The research was also retrospective, and treating physicians selected the pressure rather than assigning patients randomly.
The useful lesson is more modest: retrieval pressure can influence intermediate procedural and laboratory outcomes, and the optimal setting remains sufficiently uncertain that control and reproducibility deserve attention. The study itself noted that clinical practice uses a wide range of pressures and that excessive aspiration could theoretically damage the cumulus-oocyte complex.
What is CooperSurgical trying to improve with two presets?
The company describes the Wallace system as supporting predictable aspiration through stable pressure management and consistent device behavior. Rather than requiring the clinician or embryology team to re-establish settings from scratch, predefined options can create a standardized starting point according to the needle being used.
Standardization does not mean one pressure is ideal for every patient. Follicle size, needle geometry, physician preference and other procedural characteristics can influence the appropriate setting, which is why the new pump also permits control rather than locking users into one universal pressure.
The potential value lies in reducing avoidable variation. Assisted reproduction already contains considerable biological variability between patients and even between follicles from the same patient. Devices cannot remove that biology, but they can attempt to make the mechanical part of the process more reproducible.
Why should retrieval hardware matter when embryo genetics receives much more attention?
IVF outcomes are the product of an entire chain. Ovarian stimulation determines how follicles develop, retrieval determines which oocytes reach the laboratory, fertilization and culture influence embryo development, and transfer then confronts uterine and embryonic factors.
A technology used early in that chain can affect everything downstream if it changes how many intact mature oocytes are recovered. That does not mean improving pump stability automatically improves live-birth probability, but it explains why fertility companies continue refining needles, aspiration systems, culture dishes and incubators alongside more visible genomic technologies.
The aspiration step is also time sensitive. A clinic may perform several retrievals in a morning, and equipment that behaves predictably can support procedural efficiency and reduce troubleshooting during a stage when the physician and embryology laboratory need to remain synchronized.
Does FDA clearance mean Wallace improves pregnancy or live-birth rates?
No. CooperSurgical’s announcement describes clearance of the device and its pressure-management features; it does not establish that using Wallace increases pregnancy or live birth compared with another aspiration pump.
That distinction matters because reproductive-device marketing can easily move from engineering advantages to implied patient outcomes. The independent 400-cycle pressure study demonstrates that aspiration conditions can affect numbers of retrieved and mature oocytes, but even that study did not find a significant adjusted difference in pregnancy or live birth between its two pressure groups. It also evaluated another commercially available aspiration system rather than the Wallace pump itself.
The strongest future evidence for CooperSurgical would therefore examine reliability and workflow prospectively and, if sufficiently powered, determine whether improved consistency affects mature-oocyte yield or other clinically relevant laboratory outcomes.
Why does the clearance fit CooperSurgical’s broader fertility strategy?
CooperSurgical already supplies retrieval needles, embryo-transfer devices, culture products, genetic-testing services and other technologies used throughout assisted reproduction. Adding the aspiration pump expands control over another component of the oocyte-retrieval workflow and allows the company to design equipment and consumables around one another.
That ecosystem strategy can matter to clinics because compatibility and staff familiarity often influence purchasing decisions alongside individual product specifications. A pump paired with the company’s established Wallace retrieval needles can reduce the number of unrelated suppliers involved in one procedure.
The commercial question will nevertheless be pragmatic. IVF centers already possess functional aspiration pumps with well-established protocols, so replacing them requires a visible advantage in ease of use, pressure stability, workflow or service reliability.
CooperSurgical has cleared the regulatory hurdle for Wallace. The device now enters a field where very small procedural details can matter biologically, yet claims of improved reproductive success demand much more evidence than stable suction alone. The most defensible value proposition at launch is therefore precision and reproducibility at one critical step, not a promise of more babies from the same IVF cycle.